NCT04730284 is a NA clinical trial of Health supplements in Coronavirus, sponsored by Chinese University of Hong Kong.

Who is sponsoring NCT04730284?

NCT04730284 is sponsored by Chinese University of Hong Kong.

What drugs are being tested in NCT04730284?

Interventions in NCT04730284: Health supplements.

What condition does NCT04730284 study?

NCT04730284 studies Coronavirus.

Is NCT04730284 still recruiting?

NCT04730284 is currently status unknown. Last updated 29 January 2021.

Last reviewed 2021-01-29 · How we verify

NCT04730284

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of a Synbiotic Formula in Patient With COVID-19

Status unknown NA Last updated 29 January 2021

What this trial tests

NA trial testing Health supplements in Coronavirus in 20 participants. Status unknown.

Timeline

25 August 2020

Primary endpoint
30 September 2021

31 March 2022

Quick facts

Lead sponsor	Chinese University of Hong Kong
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	20
Start date	25 August 2020
Primary completion	30 September 2021
Estimated completion	31 March 2022
Sites	1 location across Hong Kong

Drugs / interventions tested

Health supplements

Conditions studied

Coronavirus — all drugs for Coronavirus →

Sponsor

Chinese University of Hong Kong

Who can join

18 and older, any sex, with Coronavirus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A series of microbiota were correlated inversely with the disease severity and virus load. Gut microbiota could play a role in modulating host immune response and potentially influence disease severity and outcomes.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Evidences and perspectives of the use of probiotics, prebiotics, synbiotics, and postbiotics as adjuvants for prevention and treatment of COVID-19: A bibliometric analysis and systematic review.
Xavier-Santos D, Padilha M, Fabiano GA, Vinderola G, et al · · 2022 · cited 76× · PMID 35002079 · DOI 10.1016/j.tifs.2021.12.033
Antibiotics and probiotics impact gut antimicrobial resistance gene reservoir in COVID-19 patients.
Su Q, Liu Q, Zhang L, Xu Z, et al · · 2022 · cited 18× · PMID 36201636 · DOI 10.1080/19490976.2022.2128603
Targeting the Gut Microbiota in Coronavirus Disease 2019: Hype or Hope?
Lau HC, Ng SC, Yu J. · · 2022 · cited 16× · PMID 34508775 · DOI 10.1053/j.gastro.2021.09.009
Probiotics: A gut response to the COVID-19 pandemic but what does the evidence show?
Brahma S, Naik A, Lordan R. · · 2022 · cited 11× · PMID 36184201 · DOI 10.1016/j.clnesp.2022.08.023
Nutraceuticals and pharmacological to balance the transitional microbiome to extend immunity during COVID-19 and other viral infections.
Kaushal A. · · 2024 · cited 2× · PMID 39294611 · DOI 10.1186/s12967-024-05587-9
Corrigendum to 'Evidences and perspectives of the use of probiotics, prebiotics, synbiotics, and postbiotics as adjuvants for prevention and treatment of COVID-19: A bibliometric analysis and integrative review' [Trends in Food Science & Technology 120 (2022) 174-192].
Xavier-Santos D, Padilha M, Fabiano GA, Vinderola G, et al · · 2022 · cited 2× · PMID 35125655 · DOI 10.1016/j.tifs.2022.01.028

Verify or expand the search:

Other trials of Health supplements

Trials testing the same drug.

NCT04581018 — An Evaluation of a Synbiotic Formula for Patients With COVID-19 Infection · NA · unknown

Other recruiting trials for Coronavirus

Currently open trials in the same condition.

NCT04772170 — Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies · recruiting
NCT05868239 — Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study · NA · recruiting
NCT04359836 — A Study to Explore the Role of Gut Flora in COVID-19 Infection · recruiting
NCT04376034 — Convalescent Plasma Collection and Treatment in Pediatrics and Adults · Phase 3 · recruiting
NCT04568148 — COVID-19 Biorepository · active not recruiting

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04730284 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
Last refreshed: 29 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04730284.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing